公司资料
Arrowhead Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- ARWR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
88.70 USD (+2.38%)
收盘价
最后更新: 2026年8月17日
9.98B USD
市值
股价为何变动
Following the latest company update, “People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides”, ARWR closed up 2.38% at $88.70 on Aug 17, 2026. The move occurred in the trading session associated with this company update.
公司概览
RNA Interference Platform
Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues.
REDEMPLO
REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in adults with familial chylomicronemia syndrome and is under review in additional regions.
Dual-Target Cardiometabolic RNAi
ARO-DIMER-PA is a dual-functional RNAi candidate designed to silence both PCSK9 and APOC3 in a single molecule for atherosclerotic cardiovascular disease associated with mixed hyperlipidemia.
Obesity Programs
ARO-INHBE and ARO-ALK7 are RNAi candidates targeting adipose biology. Early clinical development is assessing effects on weight loss and body composition in people with obesity.
Liver-Disease and Partnered Pipeline
ARO-PNPLA3 targets a genetically defined form of liver disease and is partnered with Madrigal. Arrowhead also advances programs across pulmonary, neuromuscular and other tissues using its TRiM platform.
未来催化剂
- European Commission decision on marketing authorization for REDEMPLO in the second quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。